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Atazanavir (ATV) plasma concentrations are influenced by CYP3A4 and ABCB1, which are regulated by the
pregnane X receptor (PXR; NR1I2). PXR expression is correlated with CYP3A4 in liver in the absence of
enzyme inducers. The PXR single nucleotide polymorphism (SNP) 63396C3T (rs2472677) alters PXR expres-
sion and CYP3A4 activity in vitro, and we previously showed an association of this polymorphism with
unboosted ATV plasma concentrations. The aim of this study was to develop a population pharmacokinetic
analysis to quantify the impact of 63396C3T and diurnal variation on ATV clearance. A population analysis
was performed with 323 plasma samples from 182 randomly selected patients receiving unboosted ATV. Two
hundred fifty-nine of the blood samples were collected at random time points, and 11 patients had a full
concentration-time profile at steady state. Nonlinear mixed effects modeling was applied to explore the effects
of PXR 63396C3T, patient demographics, and diurnal variation. A one-compartment model with first-order
absorption and lag time best described the data. Population clearance was 19.7 liters/h with interpatient
variability or coefficient of variation (CV) of 21.5%. Homozygosity for the T allele for PXR 63396 was associated
with a 17.0% higher clearance that was statistically significant. Evening dosing was associated with 34% higher
bioavailability than morning dosing. Patient demographic factors had no effect on ATV clearance. These data
show an association of PXR 63396C3T and diurnal variation on unboosted ATV clearance. The association is
likely to be mediated through an effect on hepatic PXR expression and therefore expression of its target genes
(e.g., CYP3A4, SLCO1B1, and ABCB1), which are known to be involved in ATV clearance.
Atazanavir (ATV) is an HIV protease inhibitor (PI) admin-
istered once daily (OD) at a dose of 300 mg with 100 mg of
ritonavir (RTV) to “boost” its plasma concentrations. ATV
can be used without boosting at 400 mg once daily, a dose
recently validated in a simplification trial (13). Although the
400-mg once-daily dosage is not licensed in Europe, in the
United States it is licensed for the treatment of naive patients
who cannot tolerate RTV. In a recent study in Europe, ap-
proximately 20% of ATV recipients were reported to be ad-
ministered the drug off-label with an unboosted regimen (35).
Therefore, unboosted ATV is an important alternative for
patients with RTV intolerance (19) when there are not more
effective regimens available using other drug classes.
ATV is metabolized mainly by cytochrome P450 3A4
(CYP3A4), which is present in intestine and liver. There is
marked interindividual variability in CYP3A4 expression
and function which is not explained by current knowledge of
single nucleotide polymorphisms (SNPs) in the CYP3A4
gene. ATV is also a substrate for P glycoprotein (P-gp;
ABCB1), and this transporter may influence both intestinal
absorption and excretion into the bile (9, 25). Recently, we
showed that many PIs are also substrates for OATP1B1
(encoded by the SLCO1B1 gene) (20). OATP1B1 mediates
influx of its substrates from blood into liver and therefore
facilitates their clearance from the systemic circulation. In
general, RTV boosting of PIs increases systemic exposure
and decreases interpatient variability in pharmacokinetics
(PK). This effect is mainly due to the inhibitory effect of
RTV on CYP3A4 and P-gp (34), which increases ATV
plasma concentrations in patients on boosted regimens.
Therefore, patients on unboosted ATV have considerable
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interindividual variability in PK and a higher likelihood of
suboptimal exposure (10, 21, 45). ATV plasma exposure
correlates with virological response, and a trough concen-
tration (Ctrough) of 150 ng/ml has been proposed as the
minimum effective concentration (MEC) (33).
A key regulator of phase I and II metabolism and drug
transport is the nuclear receptor (NR) pregnane X receptor
(PXR; NR1I2). PXR is activated by many PIs (40) and regu-
lates the expression of CYP3A4 (31) and ABCB1 (17), and
there is also some evidence that PXR regulates OATP1B1
expression (22, 38). PXR is a ligand-activated receptor that
regulates gene expression in response to endo- and xenobiot-
ics, but expression of PXR is correlated with that of CYP3A4
and ABCB1 in liver and peripheral blood mononuclear cells
(PBMCs) in the absence of enzyme inducers (1, 32). This is
likely to be due to a constitutive activity of the receptor, al-
though many endogenous factors such as bile acids and ste-
roids are also ligands for PXR.
Recently, three SNPs (44477T3C [rs1523130], 63396C3T
[rs2472677], and 69789A3G [rs763645]) were identified in
transcription factor binding sites of PXR regulatory regions
and were associated with altered PXR expression and activity
of CYP3A4 (27). We recently found that homozygosity of
63396C3T is associated with suboptimal ATV Ctrough (36) in
patients receiving an unboosted regimen. Identifying sources
of pharmacokinetic variability is important for clinical man-
agement and may aid optimal dose selection.
A number of previous studies have developed population
pharmacokinetic (PK) models for boosted ATV (4, 10, 14, 37).
In these studies, ATV PK was best described by a one-com-
partment model with first-order absorption. However, al-
though a number of studies have assessed the PK of unboosted
ATV (6, 16, 39), population PK models have yet to be devel-
oped and no studies have sought to incorporate pharmacoge-
netic data into ATV population PK models. Therefore, the
main purpose of this study was to develop and validate a
population PK model for unboosted ATV, to quantify the
influence of PXR 63396C3T, and to assess its frequency in
several ethnic groups.
MATERIALS AND METHODS
Patients. The PK model was developed using data from adult HIV-positive
patients receiving a regimen containing ATV 400 mg once daily and no known
concomitant interacting medication (except for tenofovir [TDF]), from three
independent cohorts. Cohort A included 11 patients with 5 or 6 plasma concen-
trations in the dosing interval and 64 patients with at least 2 random plasma
concentrations (data from 47 patients were used in a previous study) (36) from
the Department of Infectious Diseases at the University of Turin (Turin, Italy).
Cohort B included 42 patients with a single plasma concentration data point from
the Department of Infectious Diseases, Hospital Carlos III (Madrid, Spain).
Cohort C comprised 65 patients with plasma samples (data from 62 patients were
used in a previous study) (36) collected at random time points from the Liverpool
Therapeutic Drug Monitoring Registry (Liverpool, United Kingdom). A total of
323 plasma samples were available, 64 from the rich data set and 259 from the
sparse data set. Of the total 182 patients, 116 were male and 103 were receiving
TDF, and the median (range) age and body weight were 44 (19 to 74) years and
76 (46 to 115) kg, respectively.
Research ethics approval was obtained for all 3 sites participating in this study.
All samples were obtained under steady-state conditions. The following covari-
ates were available: age, gender, body weight, time postdose, concomitant anti-
retrovirals (ARVs), and other medications.
The frequency of PXR 63396C3T alleles was also investigated in 428 unre-
lated healthy individuals among a further 6 ethnic groups. Eighty-seven Ghana-
ians (2), 47 Kenyans (42), 78 Peruvians (29), 87 Saudis (42), and 45 Sudanese
(42) were all assessed at a U.S. study center (Pharmacogenetics for Every Nation
Initiative, University of North Carolina, Chapel Hill, NC), and 84 Thai subjects
were recruited and assessed at Thai study centers (Siriraj Hospital, Bangkok, and
Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand).
Quantification of plasma ATV concentrations. ATV concentrations were
quantified using a validated high-pressure liquid chromatography (HPLC)–pho-
todiode array detector (PDA) method for cohort A (12) and cohort B (43),
whereas cohort C analyses were performed using validated liquid chromatogra-
phy-tandem mass spectrometry (LC–MS-MS) methods (15). The methods were
validated internally using standard bioanalytical assay guidelines, and participa-
tion in the external KKGT (Association for Quality Assessment in Therapeutic
Drug Monitoring and Clinical Toxicology) quality control (QC) program helps
ensure that the laboratory quality assurance is maintained. For the cohort A
HPLC-PDA method, the limit of quantification (LOQ; lowest point on the
standard curve) was 25 ng/ml and the coefficient of variation (CV) for quality
control samples was 4.6 to 6.8%. For the cohort B HPLC-PDA method, the LOQ
was 50 ng/ml and the CV was 10%. For the cohort C LC–MS-MS method, the
LOQ was 47 ng/ml and the CV was 4 to 10%. All extraction procedures and
chromatographic conditions are available on request.
Genotyping analysis. Genomic DNA of the three cohorts, A, B, and C, used
for the population PK analysis and of the Thai subjects was extracted from whole
blood or plasma, and genotyping was conducted by real-time PCR-based allelic
discrimination using standard methodology or pyrosequencing (30). The real-
time PCR consisted of an initial 15-min denaturation step at 95°C followed by 45
cycles of 95°C for 15 s and 60°C for 1 min. The sequence of the forward primer
was GCACAAACATTTTCAATTTCAATGAAGTTCA, the sequence of the
reverse primer was CATTCGGAAGACTTATTCTATTCCTGTCT, the se-
quence of the C allele probe was VIC-CCATATTTTTTCTGATTAAA-NFQ
(nonfluorescent quencher), and the sequence of the T allele probe was 6-ca
rboxyfluorescein (FAM)–CCATATTTTTTTTGATTAAA-NFQ.
Ghanaians, Kenyans, Peruvians, Saudis, and Sudanese subjects were geno-
typed by pyrosequencing as previously described (30). A 253-bp fragment flank-
ing the SNP was amplified with a biotinylated forward primer (5-ATTCTGGA
TACAAGTCCCTTATGG-3) and a nonbiotinylated reverse primer (5-GGTG
GTTGGTAAGACAGATTGTCA-3) by using an annealing temperature of
58°C. For pyrosequencing, the sequencing primer was 5-GTGTTTGTTTGTT
TTTTAAT-3. The sequence analyzed was CAA/GAAAAAATATG, and a sec-
ond “A” dispensation was added after the first to take care of any unincorporated
“A” nucleotide in the sequence; the resultant dispensation order was GCAAG
AGTATG. All variants were tested for Hardy-Weinberg equilibrium by 2 test of
observed versus predicted genotype frequencies.
Population PK analysis. The PK model was developed using NONMEM
(Icon; version VI 2.0) installed under nmqual (Metrum Institute) (5, 26). Data
processing and graphical analyses were done using Microsoft Office Excel 2007
for Windows (Microsoft Corporation, Redmond. WA).
The model-building strategy was as follows. One- and two-compartment mod-
els with first- or zero-order absorption without and with lag time were fitted to
the data by using the first-order conditional method of estimation. Proportional,
additional, and combined proportional and additional error models were evalu-
ated to describe residual variability. In the model, residual variability was best
described by a purely proportional structure. Interindividual random effects were
described by an exponential model but were supported only for apparent clear-
ance (CL/F): CL/Fi  1  exp(i), where CL/Fi is the atazanavir CL/F of the ith
individual, 1 is the population parameter estimate, and i is the interindividual
variability with a mean of zero and variance 2. The minimal objective function
value (OFV; equal to 2-log likelihood) was used as a goodness-of-fit diagnostic
with a decrease of 3.84 points corresponding to a statistically significant differ-
ence between models (P  0.05, 2 distribution, 1 degree of freedom). Residual
plots were also examined. Once the appropriate structural model was estab-
lished, the following covariates were explored: body weight, age, gender, and
PXR 63396 genotypes. Tenofovir use (300 mg once daily) was also included in the
covariate analysis because an unexpected interaction has been reported (41).
Graphical methods were used to explore the relationship of covariates with
individual predicted pharmacokinetic parameters. Each covariate was intro-
duced separately into the model and retained only if inclusion in the model
produced a statistically significant decrease in OFV of 3.84 (P  0.05) and was
biologically plausible. A backward elimination step was then carried out once all
relevant covariates were incorporated, and covariates were retained if their
removal from the model produced a significant increase in OFV (	6.63 points;
P  0.01, 2 distribution, 1 degree of freedom).
Dichotomous (gender and comedications) and continuous (body weight and
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age) variables, here defined as X, were introduced into the model using the
following parameterizations, respectively:
TVCL  0  
1  1  X (1)
TVCL  0  1  
X  median value (2)
where TVCL is the typical value of ATV CL/F of the population; in equation 1,
0 is the value of CL/F for the individuals X  0 and 1 is the relative difference
in CL/F for the individuals X  1. In equation 2, for example, 0 is the typical
CL/F at the median body weight and 1 is the change in CL/F per kg.
Genotype information was coded as an index variable, which is shown for CL/F
as follows: TVCL  0  1  X1  2  X2, where 0 is the typical value of CL/F
for individuals with homozygosity for the C allele (C/C), 1 is the relative
difference in CL/F for heterozygous patients (C/T) when X1  1, and 2 is the
relative difference in CL/F for patients homozygous for the T allele (T/T) when
X2  1. Since previous studies have reported diurnal variation for ATV (46), this
was explored in combination with PXR genetics. To investigate the effect of
genetics and diurnal variation on ATV Ctrough, a relative bioavailability for ATV
administered in the evening (Fdiurnal) was added to the model. Simulated phar-
macokinetic data for ATV, stratified for time of administration and PXR geno-
type, were generated. Ninety-five percent prediction intervals of the simulated
concentrations for each category were plotted.
To assess the stability and performance of the model, a visual predictive check
was carried out, and 1,000 data sets were simulated using the parameter esti-
mates defined by the final model with the SIMULATION SUBPROBLEMS
option of NONMEM. Data sets were simulated for unboosted ATV 400 mg once
daily. From the simulated data, 95% prediction intervals (P2.5 to P97.5) were
constructed and observed data from the original data set were superimposed. If
95% of data points fell within the prediction interval, that was indicative of an
adequate model.
In addition, in order to confirm the stability and robustness of the model, a
bootstrap resampling was used. Bootstrapping was performed with the software
package Perl-speaks-NONMEM 5.1 (28). The median values and 95% confi-
dence intervals (CIs) for the parameter estimates were obtained from 200 boot-
strap replicates of the original data set and compared with the original popula-
tion parameters.
RESULTS
Population PK analysis. A total of 182 HIV-infected indi-
viduals receiving once-daily unboosted ATV at 400 mg were
included in the population analysis. Eleven of the patients had
full concentration-time profiles of 5 or 6 samples at steady state
obtained between 0 and 24 h after dosing, and the remaining
patients had blood samples drawn at random points (sparse
data set) at least 1 month after initiation of the ATV regimen.
For the latter patients, the timing of sampling relative to dose
intake and dosing with food was obtained from patient self-
reporting.
ATV pharmacokinetics were best described by a 1-compart-
ment model with first-order absorption. The introduction of a
lag time significantly improved the fit (OFV  16.8). Param-
eter estimates for the base model are summarized in Table 1.
Fixing the absorption rate constant (Ka) and lag time by using
previously published values (10, 14, 37) did not improve the
model.
A stepwise forward and backward model selection approach
was applied to identify the following as covariates: body
weight, age, gender, and comedications for CL/F. None of the
demographic covariates and comedication (tenofovir) showed
a significant decrease in objective function during the stepwise
forward inclusion and therefore were not retained in the final
model.
Pharmacogenetics. The impact on CL/F for each variant
genotype of PXR was tested using several alternative param-
eterizations shown in Table 2. A rich model which assigned a
separate fixed effect for CC, CT, and TT genotypes showed the
best fit to the data (OFV  10.5). A reduced model grouping
CC and CT genotypes also showed similar improvement in fit
(OFV  10.4), with a similar decrease in interindividual
variability. A second reduced model, grouping T allele carriers,
showed no significant model improvement (OFV  37).
Simplified models were also tried in order to estimate CL/F as
a function of the number of PXR polymorphisms, assigned a
value of 0 for C homozygotes, 1 for heterozygotes, and 2 for T
homozygotes. With this method, linear, power, and square root
models were tested. None of these models showed a significant
improvement of the objective function, and therefore, this
method was not used for the design of the final model.
The rich model showed the best fit, with general decreases in
standard errors (SEs) for all the parameters. Therefore, it was
chosen as the final model, which estimated an average CL/F of
19.7 liters/h in individuals carrying two C alleles. In heterozy-
gotes the CL/F decreased by 0.18 liters/h, and in individuals
with a T/T genotype, the model showed an increase in CL/F of
3.4 liters/h. In order to evaluate the possible impact of diurnal
variation in combination with PXR genotype, a relative bio-
availability value, Fdiurnal, was introduced. The results showed
that administration of ATV in the evening increased the bio-
availability by 34% over that with morning dosing. A summary
of the final population estimates is presented in Table 1. The
diagnostic plots for the final model showed that predicted and
observed data were in agreement (Fig. 1). The individual
weighted residuals did not reflect any particular systematic
trends.
A 95% prediction interval was generated from 1,000 simu-
lations for unboosted ATV 400 mg once daily, with the covari-
ate values of those individuals used in the building process
(Fig. 1E). Observed data from patients used in the model-
building process were superimposed onto the prediction inter-
val. Of 323 plasma concentrations, 4.3% were above P97.5 and
4.6% were below P2.5, which suggests that overall the final
model performed adequately. In addition, from the original
TABLE 1. Atazanavir parameter estimates and standard errors
obtained from the final population pharmacokinetic modela
Parameter
Estimate (% RSE) Bootstrapped median
(95% CI) in the final
modelBasic model Final model
CL/F (liters/h) 18.4 (12.4) 19.7 (6.1) 19.4 (15.9, 22.9)
V/F (liters) 122 (17.1) 136 (16.5) 133 (105.7, 158.3)
Ka (h
1) 2.3 (37.1) 2.3 (3.9) 2.7 (0.3, 11)
Lag time (h) 1.3 (0.1) 1.3 (0.005) 1.5 (0.6, 1.6)
IIV CL/F (%) 25.3 (39.3) 21.5 (26.1) 22 (15, 30)
Residual error:
proportional %








3.4 (4.7) 3.1 (0.3, 6.1)
Fdiurnal 1.34 (10) 1.30 (1.0, 1.6)
a Abbreviations: RSE, relative standard error; CL/F, apparent oral clearance;
V/F, apparent volume of distribution; Ka, absorption rate constant; IIV, inter-
individual variability; Fdiurnal, bioavailability for evening dose; CI, confidence
interval. RSE was defined as (SEestimate/estimate)  100.
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data set, 200 bootstrap replicate data sets were generated and
used to evaluate the stability of the final model. The median
values of the parameter estimates from the bootstrapping were
very similar to the mean population estimates for the final
model (Table 1). The 95% confidence interval (CI) for the
parameter estimates obtained from the bootstrap procedure
revealed adequate estimation of the PK parameters for both
fixed and random effects and robustness of the final model.
In the final model, the TT genotype increased the CL/F by
3.04 liters/h (17.2%). Heterozygosity did not significantly affect
the CL/F (0.9%), suggesting that homozygosity for the T
allele is required to influence the disposition of ATV (Fig. 2).
To investigate the effect of the combination of genetic and
diurnal variation in a population, simulated concentration-
time courses of a single dose of unboosted ATV at steady state
were performed (Fig. 3). The simulations were carried out
firstly with a population of individuals homozygous for the
common allele (63396CC) and secondly with a population of
individuals homozygous for the variant allele 63396TT, strati-
fying each group into individuals who took the drug in the
morning and individuals who took the drug in the evening.
For the morning simulations, the proportion of individuals
with subtherapeutic Ctrough was 62% 63396CC versus 80%
63396TT. For the evening simulations, the proportions were
49% 63396CC versus 70% 63396TT.
Allele frequency. The frequency of the PXR 63396T allele in
Ghanaian, Kenyan, Peruvian, Saudi, Sudanese, Italian, Span-
ish, and Thai populations was 0.39, 0.45, 0.25, 0.61, 0.61, 0.63,
0.53, and 0.6, respectively. Patients carrying the T allele in
homozygosity therefore ranged from 3.8% to 41.5% (Fig. 4).
The polymorphism was in Hardy-Weinberg equilibrium in all
populations other than Sudanese (P  0.02).
DISCUSSION
ATV is a PI with a low pill burden, favorable lipid profile,
and pharmacokinetics which allows once-daily dosing (18).
Conversely, ritonavir is associated with a number of adverse
effects, and the ability to select patients who can be safely
treated with an unboosted ATV regimen would be of clear
clinical benefit. In the present study, we evaluated the impact
of a polymorphism in PXR on ATV clearance. We have pre-
viously demonstrated that ATV concentrations are strongly
associated with homozygosity for the T allele (36). Here we
have developed and validated a model to describe unboosted
ATV PK in HIV-infected patients and evaluated the impact of
PXR 63396T and diurnal variation on ATV clearance. Of the
covariates evaluated, homozygosity for the PXR 63396T allele
was significantly correlated with ATV plasma levels, increasing
the CL/F of ATV by 17.2%.
ATV PK was best described by a one-compartment model
with first-order absorption, which is consistent with previous
studies of ritonavir-boosted ATV (4, 10, 14, 37). Although
most of the sampling was performed at certain discrete and
previously defined times (sparse data), CL/F, V/F, and in par-
ticular Ka could be estimated with acceptable standard errors
(SEs). Literature values of Ka are variable (from 0.405 to 3.4
h1) (4, 10, 14, 37) with relatively high SEs, which highlights
the difficulty in estimating the absorption phase of this drug.
Variability in Ka may be due to several factors, including drug-
drug interactions, lack of regard for food recommendations,
and suboptimal treatment adherence. Previous population
analysis has been with data from ritonavir-boosted ATV. Al-
though ritonavir is an inhibitor of P-gp and CYP3A4, which are
involved in the disposition of ATV, the presence of ritonavir
might also affect ATV absorption and hence the Ka. In our
study the Ka was estimated at 2.3 h
1, which is in the range of
the previous analyses, but with a relatively low SE (0.09 h1)
compared to studies with ritonavir-boosted ATV (4, 10, 14,
37). Therefore, despite a limited number of samples taken in
the absorption phase, the estimation of Ka was less variable,
which might be due to the absence of ritonavir. This aspect
should be taken into consideration in further analysis. Lag time
might also be affected by ritonavir; we estimated lag time at
1.30 h, which was slightly higher than that in previous studies
with boosted ATV (from 0.86 to 0.96 h). As mentioned previ-
ously, ATV absorption can be affected by many factors, and
accurate estimation of Ka and lag time can be particularly
difficult (for boosted or unboosted ATV). Characterization of
the absorption phase was not the primary focus of this analysis.
Interindividual variability was identified only for CL/F. The
data set included mainly sparse data and a limited number of
TABLE 2. Models explored to determine the influence of covariates on atazanavir pharmacokinetic parameters following
genotype variant analysisa
Covariate or genotype variant analysis Model 0 1 2 OFV P value
Covariate
Influence of sex on CL/F CL  0  (1  1  sex) 18.5 1.00 0.01 NS
Influence of wt on CL/F CL  0  1  (wt-76) 11.2 0.02 2.6 NS
Influence of age on CL/F CL  0  1  (age-44) 14.5 0.42 0.45 NS
Influence of TDF on CL/F CL  0  (1  1  TDF) 18.5 0.03 0.23 NS
Genotype variant analysis
Rich equation: influence of Het and Mut on CL/F CL  0  1  Het  2  Mut 17.6 0.20 3.04 10.50 0.01
Reduced equation 1: influence of Het on CL/F CL  0  1  (Het  Mut) 18.5 1.21 37 NS
Reduced equation 2: influence of Mut on CL/F CL  0  2  Mut 17.5 3.18 10.42 0.01
Linear equation, n  0, 1, 2 CL  0  1  n 18.5 0.46 0.13 NS
Power equation, n  0, 1, 2 CL  0  1
n 18.0 0.71 29 NS
Square root equation, n  0, 1, 2 CL  0  1  n 19.0 0.02 29 NS
a CL/F, apparent oral clearance; 0, typical value of the parameter; 1 and 2, estimates of the factor associated with the covariate; OFV, change in objective function
value; TDF, tenofovir; Het, heterozygous C/T alleles; Mut, homozygous T mutated alleles; NS, not statistically significant.
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samples in the absorption phase. This could explain the lack of
interindividual variability for the Ka. This factor may also affect
the determination of interindividual variability for volume of
distribution (V) (44).
The PK parameter results in this study showed a slightly
increased CL/F compared to data obtained with boosted ATV
presented in previous studies, which is expected due to the
absence of the boosting agent. However, the median (range)
individual estimate of half-life was 4.7 h (2.03 to 8.10 h), con-
sistent with that reported in a population analysis by Colombo
et al. (4.6 h for the unboosted ATV patients) (10). Among the
different demographic covariates tested, there was no apparent
effect of age, gender, and body weight on ATV PK parameters,
thus confirming other data (4, 10, 14, 37).
Previous studies have shown a reduction in plasma expo-
sure of boosted (41) and unboosted (24) ATV when coad-
FIG. 1. (A and B) Goodness-of-fit plots for the final pharmacokinetic model illustrating population predictions of atazanavir versus observed
concentrations (A) and individual predictions of atazanavir versus observed concentrations (B); the broken line describes the line of unity.
(C) Weighted residuals versus time postdose. (D) Population predictions of atazanavir versus weighted residuals; the thin black line is at ordinate
value zero. (E) Ninety-five percent prediction intervals (P2.5 to P97.5) determined from simulated data of unboosted atazanavir administered at
400 mg once daily. Atazanavir plasma concentrations (n  323) in 182 infected patients are superimposed, asterisks represent concentrations in
individuals carrying wild-type alleles (41 patients), open circles represent concentrations in individuals carrying heterozygous alleles (85 patients),
and open triangles represent concentrations in individuals carrying homozygous mutant alleles (56 patients).
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ministered with tenofovir. However, other studies did not
report any significant reduction of plasma concentrations of
boosted (10, 11, 14, 37) or unboosted (7, 39) atazanavir. The
present study showed no statistical differences in ATV clear-
ance in the presence of tenofovir. The mechanisms for this
possible interaction are unclear, but since tenofovir is not
metabolized by the liver, an interaction in the gut has been
proposed (41). It must be emphasized that in the present
study there were a limited number of samples in the absorp-
tion phase and current guidelines contraindicate the coad-
ministration of tenofovir and unboosted ATV (33).
For cohort C, the ethnicity was not known. However, the
majority of these 65 patients were likely to be Caucasian since
samples were obtained from the Liverpool Therapeutic Drug
Monitoring Registry, and for cohorts A and B, all the subjects
were Caucasian (self-reported). The lack of information on
ethnicity for cohort C could be a confounder in this study, but
previous studies have indicated that there is no influence of
ethnicity on plasma ATV concentrations (4, 10, 14, 37).
The correlation between PXR 63396T homozygosity and un-
boosted ATV Ctrough has been recently reported (36). Ctrough
can be considered a predictive parameter of virologic efficacy
and/or toxicity for many antiretroviral drugs. However, as ATV
is administered once daily and many patients choose to take
their medication in the evening, plasma Ctrough is not always
readily obtained, which can be a limitation in the interpreta-
tion of ATV concentrations. Using a mixed effects modeling
FIG. 2. Atazanavir individual clearances associated with the PXR
63396 genotype. Wt, wild-type C/C alleles; Het, heterozygous C/T
alleles; Mut, homozygous T mutant alleles. Median values are shown
by thick horizontal lines.
FIG. 3. Steady-state 95% prediction intervals (P2.5 to P97.5) determined from simulated data of unboosted ATV stratified for PXR 63396T3C
genotype and for evening versus morning dosing. The mean population prediction (continuous thick line) and the 95% prediction interval (gray
area) are represented for each category. The broken horizontal line is at an ordinate value of 0.150 mg/liter (proposed minimum effective
concentration [MEC]). (A) Steady-state ATV concentrations predicted for patients with PXR 63396TT with morning dose (median time to below
MEC  19.32 hours). (B) Steady-state ATV concentrations predicted for patients with PXR 63396TT receiving an evening dose (median time to
below MEC  21 hours). (C) Steady-state ATV concentrations predicted for patients with PXR 63396CC with morning dose (median time to below
MEC  22.15 hours). (D) Steady-state ATV concentrations predicted for patients with PXR 63396CC with evening dose (median time to below
MEC  24.08 hours).
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approach with data from three distinct cohorts, we have been
able to confirm the impact of this polymorphism on the un-
derlying mechanism of metabolic clearance, which lends fur-
ther causal support to this observation.
The 63396C3T polymorphism is located in intron 1 of
the PXR gene and is in linkage disequilibrium with three
other polymorphisms [63704A	G, 63813(CAAA)(CA), and
65104T	C]. The SNP itself is located in a putative hepatocyte
nuclear factor 3 (HNF3) binding site and was previously
associated with CYP3A4 activity in primary human hepato-
cytes with a trend for an association with PXR expression (27).
Therefore, the putative mechanism for the association with
ATV clearance is that individuals with the T allele have higher
expression of PXR, resulting in higher constitutive activity of
the nuclear receptor. Since PXR regulates CYP3A4, ABCB1,
and possibly SLCO1B1 and ATV is a substrate for all of these
proteins, these individuals would then exhibit higher clearance
as a result of higher influx into the liver, higher metabolism,
and higher efflux into bile. Consistent with our previous study
on this polymorphism and unboosted ATV (36), the effect on
PK phenotype was observed only when the polymorphism was
carried in homozygosity, indicating that the allele is recessive.
Further studies are warranted to determine whether polymor-
phisms in PXR target genes also influence ATV concentra-
tions.
A potential utility of pharmacogenetic testing is in opti-
mizing dose and/or choice of regimen in different ethnicities
or subpopulations. Therefore, we also investigated the fre-
quency of the PXR 63396T allele across different ethnic
groups and observed considerable differences in the fre-
quency. Of note, the frequency of the T allele was lower in
Ghanaian subjects than in Sudanese subjects. Also of inter-
est was that the T allele was more frequent in Spanish
individuals than in native Peruvians, and this large differ-
ence in frequency may have implications for dosing of
CYP3A4 substrates in Latin America, a possibility which
warrants further investigation. Conversely, no marked dif-
ferences in allele frequency were observed between Thai
and Caucasian individuals, and this polymorphism therefore
does not explain why lower-dose-boosted ATV (200/100 mg
once daily [OD]) has pharmacokinetic parameters in Thai
patients similar to those reported for the standard dose
(300/100 mg OD) in Caucasians (3, 8).
There are likely to be a number of genes that contribute to
the variability in plasma concentrations of unboosted ATV.
The strength of the association shown here with the PXR
63396C3T polymorphism is such that it is unlikely to be im-
plemented as a clinical test in its own right. However, as other
pharmacogenetic associations emerge, they can be incorpo-
rated into population PK models in order to quantify their
contribution to clearance and plasma concentrations. The ex-
tent of this contribution can then be used to assign weighting to
individual loci in order to construct composite genetic models,
which are more likely to have clinical utility. In addition, the
population PK model presented here may have value for pre-
dicting Ctrough from sparse sampling data and for designing
optimal sampling strategies for clinical studies where exposure
is the parameter of interest.
Diurnal variation of twice-daily ATV plasma concentra-
tions has previously been reported (23), showing that morn-
ing dosing results in significantly lower Ctrough than does
evening dosing. During routine therapeutic drug monitor-
ing, ATV Ctrough values following evening dosing are diffi-
cult to obtain due to clinic opening hours and patient avail-
ability. In our study, some ATV concentrations were
collected in the morning at circa 12 h after the last evening
dose and, therefore, using nonlinear mixed effects analysis,
we were able to simulate the effect of diurnal variation on
ATV plasma concentrations for a once-daily regimen. The
results show that evening dosing significantly decreases the
risk of subtherapeutic concentrations. Moreover, these data
indicate that the “safest” group of patients were those who
had the PXR 63396CC genotype and who took their medi-
cation in the evening. A major strength of population PK
modeling is the ability to integrate genetic and demographic
data to give a greater understanding of the key factors
influencing plasma concentrations.
In conclusion, the PK parameters of unboosted ATV in
HIV-infected patients were adequately described by the
population model. The data support an association between
PXR 63396C3T and unboosted ATV clearance. This asso-
ciation is likely to be mediated through an effect on hepatic
PXR expression and therefore expression of its coordinately
regulated target genes (e.g., CYP3A4 and ABCB1), which
are involved in ATV clearance. The frequency of this poly-
morphism varies significantly across populations, and pro-
spective studies are now required to accurately determine its
clinical value in different ethnic groups.
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